New Dual-Action antibodies take on tough esophageal cancer

NCT ID NCT04785820

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested two experimental drugs, lomvastomig and tobemstomig, against the standard immunotherapy nivolumab in 190 people with advanced esophageal cancer that had worsened after chemotherapy. The drugs are bispecific antibodies designed to block two immune checkpoints at once, potentially boosting the immune system's attack on cancer cells. The study compared overall survival and side effects among the three groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bispecific antibodies (lomvastomig and tobemstomig)
What this could lead to
If successful, these new drugs could offer a more effective treatment option for advanced esophageal cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is an early-phase trial with only 190 participants, and one drug arm was stopped early for strategic reasons. The results may not lead to a new approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • APHP - Hopital Saint Antoine

    Paris, 75571, France

  • Ac?badem Altunizade Hastanesi

    Istanbul, Turkey (Türkiye)

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department

    Erzurum, 25240, Turkey (Türkiye)

  • Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della

    Udine, Friuli Venezia Giulia, 33100, Italy

  • Bashkirian Republican Clinical Oncology Dispensary

    Ufa, Bashkortostan Republic, 450054, Russia

  • Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital

    Adana, 01230, Turkey (Türkiye)

  • Centre Leon Berard

    Lyon, 69373, France

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, F5300COE, Argentina

  • Centrum Onkologii w Bydgoszczy

    Bydgoszcz, 85-796, Poland

  • Changhua Christian Hospital

    Chang-hua, 500, Taiwan

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, 58128, South Korea

  • Communal Non profit Enterprise Regional Center of Oncology

    Kharkiv, Kharkiv Governorate, 61070, Ukraine

  • Complejo Hospitalario de Navarra

    Pamplona, Navarre, 31008, Spain

  • Curie Oncology

    Singapore, 329563, Singapore

  • Dicle Uni Medical Faculty

    Diyarbakır, 10000, Turkey (Türkiye)

  • Fakultni nemocnice Olomouc

    Olomouc, 779 00, Czechia

  • First Moscow State Medical University n.a. I.M. Sechenov

    Moscow, Moscow Oblast, 119991, Russia

  • Group of companies "Medci"

    Moskva, Moscow Oblast, 105229, Russia

  • Hopital Claude Huriez

    Lille, 59037, France

  • Hopital Timone Adultes

    Marseille, 13385, France

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Clínic i Provincial

    Barcelona, 08036, Spain

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • ICO Rene Gauducheau

    Saint-Herblain, 44805, France

  • IRCCS Istituto Oncologico Veneto (IOV)

    Padova, Veneto, 35128, Italy

  • Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department

    Malatya, 44280, Turkey (Türkiye)

  • Inst. Alexander Fleming

    Buenos Aires, C1426ANZ, Argentina

  • Institut régional du Cancer Montpellier

    Montpellier, 34298, France

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, 01246-000, Brazil

  • International Cancer Institute (ICI)

    Eldoret, 30100, Kenya

  • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS

    Meldola, Emilia-Romagna, 47014, Italy

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

    Szolnok, 5004, Hungary

  • Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II

    Krakow, 31-202, Poland

  • MEDSI Clinical Hospital on Pyatnitsky Highway

    Moscow, Moscow Oblast, 143422, Russia

  • Masaryk?v onkologický ústav

    Brno, 656 53, Czechia

  • NIO im Marii Sklodowskiej-Curie

    Warsaw, 02-034, Poland

  • National Cancer Centre

    Singapore, 168583, Singapore

  • National Taiwan University Hospital

    Zhongzheng Dist., 10048, Taiwan

  • Nottingham City Hospital

    Nottingham, NG5 1PB, United Kingdom

  • Odense Universitetshospital, Onkologisk Afdeling R

    Odense C, 5000, Denmark

  • Ramathibodi Hospital

    Bangkok, 10400, Thailand

  • Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary

    Sumy, 40005, Ukraine

  • Rigshospitalet

    København Ø, 2100, Denmark

  • Seoul National University Bundang Hospital

    Seongnam-si, 13605, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Siriraj Hospital

    Bangkok, 10700, Thailand

  • Songklanagarind Hospital

    Songkhla, 90110, Thailand

  • Szpital Morski im. PCK

    Gdynia, 81-519, Poland

  • Taipei Veterans General Hospital

    Taipei, 112201, Taiwan

  • The Aga Khan University-Kenya.

    Nairobi, 00100, Kenya

  • Van Yuzuncu Yil University Hospital

    Van, Turkey (Türkiye)